- Started or switched to new androgen deprivation therapy (ADT) (e.g. Luteinizing Hormone-Releasing Hormone (LHRH) agonists and antagonists, anti-androgens, estrogens, abiraterone, enzalutamide, etc.) within 4 weeks prior to enrolment or planning to start new treatment prior to 1st Ra-223 injection